High-dose thiotepa, in conjunction with melphalan, followed by autologous hematopoietic stem cell transplantation in patients with pediatric solid tumors, including brain tumors - Summary - MDSpire

High-dose thiotepa, in conjunction with melphalan, followed by autologous hematopoietic stem cell transplantation in patients with pediatric solid tumors, including brain tumors

  • By

  • Junichi Hara

  • Kimikazu Matsumoto

  • Naoko Maeda

  • Mariko Takahara-Matsubara

  • Saori Sugimoto

  • Hiroaki Goto

  • November 3, 2022

  • 0 min

Share

Objective:

Specify primary endpoints for safety and efficacy.

Key Findings:
  • Clarify context of survival rates and include specific patient population data.
Interpretation:

Mention implications for clinical practice.

Limitations:
  • Add potential biases due to non-comparative study design.
Conclusion:

Emphasize the need for future studies to validate findings.

Original Source(s)

High-dose thiotepa, in conjunction with melphalan, followed by autologous hematopoietic stem cell transplantation in patients with pediatric solid tumors, including brain tumors

  • by Junichi Hara, Kimikazu Matsumoto, Naoko Maeda, Mariko Takahara-Matsubara, Saori Sugimoto, Hiroaki Goto

  • November 3, 2022

Related Content

Changes in survival over time for primary brain and other CNS tumors in the United States, 2004–2017

Focused ultrasound-mediated enhancement of blood–brain barrier permeability for brain tumor treatment: a systematic review of clinical trials

Development and validation of a predictive nomogram for leptomeningeal metastasis risk in NSCLC brain metastases: role of tumor location, driver mutations, and stereotactic radiosurgery